Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
Diaceutics PLC said on Tuesday it swung to a pretax profit in 2021 and posted an increase in annual revenue.
The diagnostic commercialisation company for precision testing posted a pretax profit of £462,000 in 2021, compared to a loss of £682,000 million in 2020.
Diaceutics also increased its revenue by 10% to £13.9 million from £12.7 million.
It explained that 60% of its revenue came from the DXRX platform, far above the 20% target set by the company. The DXRX platform integrates diagnostic testing data from a global network for laboratories.
‘We are confident that Diaceutics is positioned to maximise the advantage it has as the market-first digital diagnostics commercialisation platform,’ the Belfast-based company said.
Diaceutics shares were 0.5% higher at 103.48 pence each in London on Tuesday afternoon.
Copyright 2022 Alliance News Limited. All Rights Reserved.